Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27755762 | 0.82 | CNR2 (0.56) | CNR2NR3C1BRD4CREBBPJAK1 | |
| SCHEMBL27776594 | 0.78 | CNR2 (0.54) | CNR2NR3C1BRD4CREBBPJAK1 | |
| SCHEMBL2169026 | 0.77 | CNR2 (0.64) | CNR2ATRALDH1A1 | |
| SCHEMBL2079150 | 0.76 | CNR2 (0.63) | CNR2BRD4CREBBPALDH1A1 | |
| SCHEMBL2079630 | 0.74 | CNR2 (0.60) | CNR2BRD4CREBBPATRALDH1A1 | |
| SCHEMBL2079633 | 0.74 | CNR2 (0.60) | CNR2BRD4CREBBPATRALDH1A1 | |
| SCHEMBL3800139 | 0.72 | CNR2 (0.52) | CNR2BRD4CREBBPATRAOC3 | |
| SCHEMBL29195938 | 0.72 | CNR2 (0.64) | CNR2BRD4CREBBPATR | |
| SCHEMBL16773016 | 0.72 | CNR2 (0.69) | CNR2ATRALDH1A1 | |
| SCHEMBL2076573 | 0.72 | HSP90AB1 (0.57) | CNR2NR3C1BRD4CREBBPATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | HSP90AB2P, HSPA2, HSP90AB1 | CNR2 4210/4885NR3C1 2675/4885BRD4 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.